Myonexus

OverviewSuggest Edit

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing treatments for Limb-girdle muscular dystrophy Types 2D, 2B, 2E, 2L, and 2C. 

TypePrivate
Founded2017
HQColumbus, US
Websitemyonexustx.com

Latest Updates

Employees (est.) (Nov 2019)35(+192%)
Cybersecurity ratingAMore

Key People/Management at Myonexus

Michael Triplett

Michael Triplett

President & Chief Executive Officer
Bruce Halpryn

Bruce Halpryn

Secretary & Chief Operating Officer
Louise Rodino-Klapac

Louise Rodino-Klapac

Chief Scientific Officer
Peter Kleinhenz

Peter Kleinhenz

Treasurer & Chief Financial Officer
Show more

Myonexus Office Locations

Myonexus has an office in Columbus
Columbus, US (HQ)
Columbus, OH, USA
Show all (1)

Myonexus Financials and Metrics

Summary Metrics

Founding Date

2017

Myonexus total Funding

$3.3 m

Myonexus latest funding size

$2.50 m

Time since last funding

3 years ago

Myonexus investors

Myonexus's latest funding round in December 2017 was reported to be $2.5 m. In total, Myonexus has raised $3.3 m
Show all financial metrics

Myonexus Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Myonexus Online and Social Media Presence

Embed Graph

Myonexus News and Updates

Sarepta stock up 3% after announcing acquisition of gene-therapy company Myonexus

Shares of Sarepta Therapeutics Inc. rose 3% in premarket trade Wednesday after the company announced it would acquire biotech Myonexus Therapeutics and its five gene-therapy drug candidates for the treatment of limb-girdle muscular dystrophy, a group of genetic neuromuscular diseases. The acquisit…

Sarepta to buy gene therapy developer Myonexus for $165 mln

Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.

Sarepta Exercises Option to Acquire Myonexus Therapeutics

-- Exercise Fee is $165 Million -- -- Sarepta to Acquire Myonexus’ Portfolio of Five Gene Therapy Candidates to Treat Distinct Forms of Limb-Girdle Muscular Dystrophy (LGMD) --

Sarepta Exercises Option to Acquire Myonexus Therapeutics

-- Exercise Fee is $165 Million -- -- Sarepta to Acquire Myonexus’ Portfolio of Five Gene Therapy Candidates to Treat Distinct Forms of Limb-Girdle Muscular Dystrophy (LGMD) --

Myonexus Blogs

Myonexus Frequently Asked Questions

  • When was Myonexus founded?

    Myonexus was founded in 2017.

  • Who are Myonexus key executives?

    Myonexus's key executives are Michael Triplett, Bruce Halpryn and Louise Rodino-Klapac.

  • How many employees does Myonexus have?

    Myonexus has 35 employees.

  • Who are Myonexus competitors?

    Competitors of Myonexus include MODAG, Clover Biopharmaceuticals and Neuro-Bio.

  • Where is Myonexus headquarters?

    Myonexus headquarters is located at Columbus, OH, USA, Columbus.

  • Where are Myonexus offices?

    Myonexus has an office in Columbus.

  • How many offices does Myonexus have?

    Myonexus has 1 office.